The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trial
- 1 May 2024
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (8) , 1921-1931
Abstract
Aims: Corticosteroids are the treatment of choice for many inflammatory diseases but often lead to adverse effects, including hyperglycaemia. This study investigated the mechanisms driving differential effects on glucose control for AZD9567, an oral nonsteroidal selective glucocorticoid receptor modulator vs. prednisolone in 46 patients with type 2 diabetes mellitus.Methods: In this randomized, double‐blind, 2‐way cross‐over study (NCT04556760), participants received either AZD9567 72 mg and prednisolone 40 mg daily (cohort 1); AZD9567 40 mg and prednisolone 20 mg daily (cohort 2); or placebo and prednisolone 5 mg daily (cohort 3). Treatment duration was 3 days with a 3‐week washout between treatment periods. Glycaemic control was assessed after a standardized meal and with continuous glucose monitoring.Results: A significant difference between AZD9567 and prednisolone in favour of AZD9567 was observed for the change from baseline to Day 4 glucose excursions postmeal in cohort 1 (glucose area under the curve from 0 to 4 h −4.54%; 95% confidence interval [CI]: −8.88, −0.01; P = .049), but not in cohort 2 (−5.77%; 95% CI: −20.92, 12.29; P = .435). In cohort 1, significant differences between AZD9567 and prednisolone were also seen for the change from baseline to day 4 in insulin and glucagon secretion postmeal (P < .001 and P = .005, respectively) and change from baseline to Day 4 in GLP‐1 response (P = .022). Significant differences between AZD9567 and prednisolone for 24‐h glucose control were observed for both cohort 1 (−1.507 mmol/L; 95% CI: −2.0820, −0.9314; P < .001) and cohort 2 (−1.110 mmol/L; 95% CI −1.7257, −0.4941; P < .001).Conclusion: AZD9567 significantly reduced treatment‐induced hyperglycaemia compared with prednisolone.Keywords
All Related Versions
Funding Information
- AstraZeneca
This publication has 14 references indexed in Scilit:
- AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double‐blind, efficacy, and safety studyClinical and Translational Science, 2023
- COVID‐19 and dexamethasone‐induced hyperglycaemia: Workload implications for diabetes inpatient teamsDiabetic Medicine, 2021
- Estimation of Equipotent Doses for Anti‐Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor ModulatorCPT: Pharmacometrics & Systems Pharmacology, 2020
- Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trialsThe Lancet Rheumatology, 2020
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEuropean Heart Journal, 2019
- Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect ProfileJournal of Medicinal Chemistry, 2018
- Long-term Systemic Corticosteroid Exposure: A Systematic Literature ReviewClinical Therapeutics, 2017
- Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantationNephrology Dialysis Transplantation, 2013
- Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cellsCellular Signalling, 2011
- Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitusOphthalmology, 2005